Drugs / L-Threonic Acid Magnesium Salt
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02558790 | Mar 2016 → Oct 2017 | attention deficit-hyperactivity disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02237235 | Aug 2014 → Aug 2017 | schizoaffective disorder, schizophrenia | Northwestern University | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-09-13 | Neurocentria, Inc. | Results Neurocentria Demonstrates that Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice neurocentria.com ↗
The report, which appeared in the September 13th issue of Molecular Brain, shows that a newly developed magnesium compound known as L-Threonic acid Magnesium salt (L-TAMS, aka Magnesium-L Threonate) can prevent cognitive impairment when administered to mice with early stage AD. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2014-09-13 | Neurocentria, Inc. | Neurocentria Demonstrates that Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice neurocentria.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-Threonic acid Magnesium salt | “Active ingredient: L-Threonic acid Magnesium salt.” NCT02237235 ↗ |
| Known as | L-TAMS | “L-Threonic Acid Magnesium Salt (L-TAMS)” NCT02558790 ↗ |
| Route | Oral | “1 g (2 pills) by mouth once daily in the evening for 9 weeks” NCT02237235 ↗ |